Reimbursement Briefs: Pfizer Joins Big Data Group; Part D Protected Classes; Wikipedia Partners With Cochrane Collaboration
Executive Summary
Pfizer is among seven organizations joining the Optum Labs research collaborative; CMS Coverage and Analysis Group Director Louis Jacques moving to private sector, more news in brief.
You may also be interested in...
Mental Health Drugs Face Contracting Challenges From Part D Formulary Proposal
CMS estimates that removing antidepressants, antipsychotics and immunosuppressants from “protected class” status in Medicare Part D could save $720 million between 2016 and 2019.
Final Medicare Coverage-With-Evidence-Development Guidance Delayed By CMS Staff Cuts
The CMS coverage and analysis group has had to divert its attention from finishing a CED guidance to finalizing proposed changes to the process for awarding Medicare coverage for investigational device trials, primarily due to staff cuts, says Louis Jacques, who heads the group.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.